43 results about "Staphylococcus aureus infections" patented technology

The invention relates to the technical field of biological medicine, in particular to an antibody aiming at staphylococcus aureus enterotoxin B and application thereof. A heavy chain variable region of the antibody provided by the invention comprises CDR sequences as shown in SEQ ID NO.1-3, and a light chain variable region of the antibody comprises CDR sequences as shown in SEQ ID NO.9-11. The antibody has high affinity, can specifically bind to staphylococcus aureus SEB, can block binding of SEB and MHC II / TCR, significantly inhibits cytokine storm, shows a dose-dependent protection effect in an MRSA systemic infection model, and can be used for preparing an MRSA systemic infection model. The monoclonal antibody can be used for treating, preventing or diagnosing the infection of the staphylococcus aureus, provides a solution of non-antibiotic therapy for SEB poisoning and drug-resistant staphylococcus aureus infection, and has important clinical and public health values.

This invention discloses the application of ferrous ions in the preparation of products for treating bacterial infections, belonging to the field of pharmaceutical technology. Antibacterial activity tests of ferrous ions against Staphylococcus aureus showed strong bactericidal effects, with a survival rate of less than 0.001% against Staphylococcus aureus and less than 0.01% against methicillin-resistant Staphylococcus aureus (MRSA). The use of ferrous ion-containing hydrogels in the treatment of keratitis and skin wound infections significantly reduced the risk of MRSA infection in the lungs and effectively prevented the proliferation and spread of microorganisms in the body, revealing that drugs containing ferrous compounds can be used to treat Staphylococcus aureus infections, including MRSA.

The invention is applicable to the technical field of genetic engineering, and provides a vaccine for preventing and treating staphylococcus aureus mastitis and application of the vaccine. A recombinant bacillus subtilis construction method comprises the following steps: taking a DNA sequence as shown in SEQ ID NO.3 as a template, and performing PCR amplification to obtain a PCR product sequence; connecting the PCR product to a pHT43 vector, and converting the pHT43 vector into a competent cell DH5alpha, so as to obtain a recombinant plasmid pHT43-cCsa; the method comprises the following steps: transforming a recombinant plasmid pHT43-cCsa into a competent cell of bacillus subtilis WB800N, taking pHT43-F and pHT43-R as primers, and screening a positive transformant through a PCR (Polymerase Chain Reaction) technology; the recombinant bacillus subtilis for expressing the staphylococcus aureus Csa protein is constructed by utilizing a homologous recombination technology, so that pathological injury caused by staphylococcus aureus infection can be reduced, and staphylococcus aureus mastitis of dairy cattle can be prevented.

The application belongs to the field of antibacterial two-dimensional nanomaterial Mxene catalysts, and particularly relates to a monolayer W@MoS2 nanosheet as well as a preparation method and application thereof. The method comprises the following steps: 1) dissolving water-soluble molybdate and water-soluble tungstate in water to obtain a mixed solution; 2) adding a sulfur source and an organic solvent to the mixed solution, and then performing reaction after mixing, and drying to obtain a powder. The monolayer W@MoS2 nanosheet has a unique two-dimensional planar structure, a large specific surface area, and good optical and electronic properties, and has high light-heat absorption in the near-infrared two region, i.e., the light-heat conversion efficiency is improved. Meanwhile, the peroxidase-like activity of the monolayer W@MoS2 nanosheet material realizes efficient light-heat amplification, can treat methicillin-resistant Staphylococcus aureus infection, and avoids heat therapy damage to normal tissues.

The invention relates to a PPP2CB phosphatase target small molecule compound and application thereof, and belongs to the field of biological medicine. The invention provides a small molecule compound C16H16N4O, which is specifically combined with a PPP2CB catalytic subunit, and by enhancing the activity of PPP2CB phosphatase, the serine / threonine phosphorylation level of ERK, MAPK, JAK and other kinases in macrophages is remarkably reduced, and the activation of NF-kappa B, JAK-STAT and MAPK-ERK inflammation signal pathways is blocked. The compound is suitable for treating inflammatory storm caused by SARS-CoV-2, influenza virus and staphylococcus aureus infection. In an SARS-CoV-2 infection model, the survival rate of the mice is increased from 0 to 50%; the lung pathological injury is relieved after influenza virus infection. Sepsis caused by staphylococcus aureus USA300 is effectively inhibited, and the death rate is reduced. The clinical transformation potential is realized.

The application discloses an antibody against Staphylococcus aureus IsdB and application thereof. The antibody comprises a heavy chain variable region and a light chain variable region, the amino acid sequences of CDR1, CDR2 and CDR3 of the heavy chain variable region are respectively shown as SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and the amino acid sequences of CDR1, CDR2 and CDR3 of the light chain variable region are respectively shown as SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11. In addition, the application further discloses a product for detecting Staphylococcus aureus IsdB and application of the antibody in preparation of a diagnosis, prevention and / or treatment of diseases related to Staphylococcus aureus infection. The application provides a new idea for detection of Staphylococcus aureus IsdB and treatment of related diseases, and has a wide application prospect.

The invention provides an application of SX-682 in preparation of a drug for resisting staphylococcus aureus infection, and the SX-682 has a CAS number of 1648843-04-2. According to the technical scheme, the novel medical application of the SX-682 is disclosed, and the SX-682 has better antibacterial activity on staphylococcus aureus and can inhibit formation of biofilms including methicillin-sensitive staphylococcus aureus (MSSA) and methicillin-resistant staphylococcus aureus (MRSA). The SX-682 has no significant toxicity to human cytotoxicity in the bacteriostatic concentration range, and provides key support for subsequent anti-infection application of the SX-682.

The invention relates to the technical field of nano-medicine carriers, in particular to composite drug-loaded nanoparticles based on acylated polysaccharide and berberine as well as a preparation method and application of the composite drug-loaded nanoparticles. The preparation method comprises the following steps: carrying out acylation modification on natural polysaccharide by using a basic catalyst and acid anhydride to obtain acylated natural polysaccharide; wherein the acylation modification mode comprises acetylation modification or propionylation modification; in an organic solvent, the berberine and the acylated natural polysaccharide are subjected to encapsulation treatment, and the composite drug-loaded nanoparticles based on the acylated polysaccharide and the berberine are obtained. According to the preparation method, the natural polysaccharide is subjected to acylation modification, the hydrophobicity of the natural polysaccharide is adjusted, and the encapsulation efficiency of berberine is remarkably improved. On one hand, the composite drug-loaded nanoparticles can significantly improve the bioavailability of berberine and prolong the in-vivo action time of berberine, and on the other hand, the composite drug-loaded nanoparticles can promote the repair and healing of wounds infected by staphylococcus aureus and reduce the drug resistance of staphylococcus aureus.

The application discloses an antibacterial peptide derived from the skin of bullfrog and application thereof, and the amino acid sequence of the antibacterial peptide is GSVGPVGPR (as shown in SEQ ID NO:1), and the molecular weight is 824.4504 g / mol. The antibacterial peptide has obvious inhibiting effect on Staphylococcus aureus, and can be used for preparing a medicine for preventing or inhibiting Staphylococcus aureus infection. Meanwhile, the antibacterial peptide and vitamin A have a significant synergistic bactericidal effect on Staphylococcus aureus. The antibacterial peptide and vitamin A can significantly reduce the use concentration of single component, improve the antibacterial efficiency, overcome the bacterial drug resistance problem, and can be used for preparing antibacterial medicines, skin external preparation, medical dressings, feed additives and food preservatives.

The application discloses an antibody-antibiotic conjugate and application thereof, and a structural formula of the antibody-antibiotic conjugate is shown as formula (I) and is composed of a payload antibiotic, a monoclonal antibody targeting Kdo monosaccharide and an enzyme-sensitive linker; the antibody-antibiotic conjugate has strong affinity to Kdo antigen and can be combined with Staphylococcus aureus of different serotypes. Enzymatic treatment of the antibody-antibiotic conjugate can release free antibiotics to improve the bactericidal efficiency on Staphylococcus aureus; the antibody-antibiotic conjugate can effectively kill intracellular bacteria which are difficult to be affected by traditional small-molecule antibiotics through the mediation of the antibody; in the application of a Staphylococcus aureus-induced mouse pneumonia and nephritis model, the antibody-antibiotic conjugate can effectively remove bacteria in the lung and kidney, and the therapeutic effect is better than that of vancomycin. Therefore, the antibody-antibiotic conjugate has potential application in the development of Staphylococcus aureus infection drugs.

The invention discloses a preparation method of a phenol derivative capable of effectively inhibiting staphylococcus aureus, and belongs to the technical field of synthesis and application of medical intermediates. The preparation method comprises the following steps: under the conditions of protective atmosphere and illumination, carrying out an addition reaction on 4-benzal-2, 6-di-tert-butylcyclohexane-2, 5-diene-1-ketone and cyclohexane under the action of 4-nitrophthalonitrile, so as to obtain the 2, 6-di-tert-butyl-4-(cyclohexyl (phenyl) methyl) phenol. The preparation method has the advantages of simplicity in operation, mild reaction conditions, low cost of used reagents, high yield and the like, is favorable for realizing large-scale production, provides a key intermediate support for developing low-cost and high-activity anti-staphylococcus aureus drugs, and has important significance in relieving clinical drug-resistant staphylococcus aureus infection treatment dilemma.

The application belongs to the technical field of microorganisms, and discloses application of shikimic acid in preparation of antibacterial preparations for inhibiting staphyloxin synthesis. It is found that shikimic acid can inhibit synthesis of staphyloxin in methicillin-resistant Staphylococcus aureus (MRSA), reduce tolerance of the bacteria to oxidative stress, induce accumulation of intracellular active oxygen, and damage cell membrane structure and function, including reducing cell membrane order, inducing membrane depolarization, increasing membrane permeability, and leading to ATP leakage and energy metabolism disorder. A new strategy and preparation direction are provided for clinical treatment of multi-drug resistant Staphylococcus aureus infection, and the application has important theoretical value and application prospect.

The invention discloses a manganese-based nano-enzyme preparation method, a manganese-based nano-enzyme product and an application of the manganese-based nano-enzyme product in antibiosis, and belongs to the technical field of nano-enzymes and biomedicine nanotechnology. According to the preparation method, KMnO4 and C18H34O2 are used as raw materials, and the manganese-based nano-enzyme is prepared through a water phase method. The nano-enzyme shows good application prospects in removing bacterial biofilms, inhibiting bacteria from forming biofilms and treating wound infection models. Animal experiments show that the hydrogel has excellent biocompatibility, is free of toxic accumulation, and can effectively treat mouse wound staphylococcus aureus infection and promote wound healing.

The invention discloses a transgenic animal antibody high-yield expression system based on double-copy site-specific integration and application of the transgenic animal antibody high-yield expression system. According to the invention, dual-copy anti-staphylococcus aureus enterotoxin B (SEB) monoclonal antibody genes are integrated at safe sites of mouse ROSA26 and H11 in a targeting manner, so that the whole-body high-level stable expression of the antibody in a mouse body is realized, and the yield and neutralizing activity of the antitoxin antibody are remarkably improved. The invention provides a new thought and a new strategy for the development of a low-cost and high-efficiency therapeutic antibody bioreactor. Besides, the constructed SEB antibody gene animal model provides an important tool for research on staphylococcus aureus infection resistance, provides a potential model animal solution for disease prevention and control of animal husbandry, and has good application value and industrial transformation prospect.

The invention particularly discloses application of a lactylation inhibitor in preparation of a medicine for treating staphylococcus aureus biofilm related infection, and relates to the technical field of biological medicine. The invention provides application of a SarA protein K72 site lactic acid inhibitor in preparation of a medicine for preventing and / or treating staphylococcus aureus infection of diabetic patients, and discloses that high glucose promotes formation of a staphylococcus aureus biofilm through lactic acid modification on a SarA K72 site.

The invention relates to the field of biological medicine and immunology, in particular to preparation and application of an anti-staphylococcus aureus enterotoxin B antibody. A heavy chain variable region of the antibody SEB-A8 provided by the invention comprises CDR sequences as shown in SEQ ID NO: 1-3, a light chain variable region of the antibody SEB-A8 comprises CDR sequences as shown in SEQ ID NO: 9-11, and the antibody SEB-A8 has important application value in treatment, prevention or diagnosis of staphylococcus aureus infection. Experimental data show that the antibody can effectively neutralize the superantigen activity of SEB and significantly improve the survival rate of MRSA infected mice, has a dose-dependent protection effect, can be used as a non-antibiotic treatment strategy, is used for treatment of methicillin-resistant staphylococcus aureus infection, has great significance in controlling development of bacterial drug resistance, and has a broad application prospect. And a new research direction is provided for clinical anti-infection treatment.

The invention discloses a covalent organic framework polymer capable of selectively inactivating staphylococcus aureus and application of the covalent organic framework polymer. The covalent organic framework polymer is obtained by polymerization of a ruthenium complex and heteropoly acid through aminal reaction, and the ruthenium complex is bis (hexafluorophosphate) tris (5, 5 '-bis (diethoxymethyl)-2, 2'-dipyridyl) ruthenium; the preparation method comprises the following steps: adding bis (hexafluorophosphate) tris (5, 5 '-bis (diethoxymethyl)-2, 2'-dipyridyl) ruthenium and Tris-V6O19 into an organic solvent, and carrying out solvothermal reaction, so as to obtain the covalent organic framework polymer. The m-RuV-COF prepared by the invention can selectively inactivate staphylococcus aureus at an extremely low concentration, and has a very small inactivation effect on escherichia coli. And a new effective strategy is provided for specifically solving the problem of staphylococcus aureus infection.

The invention discloses an antigen protein as well as a preparation method and application thereof. The antigen protein comprises a soluble catalytic domain of the membrane protein LCP or a variant thereof. The antigen protein can be used for preventing and treating staphylococcus aureus infection, especially drug-resistant bacteria infection, and clinical related infectious diseases caused by the staphylococcus aureus infection, so that more stable broad-spectrum protection on staphylococcus aureus infection, especially drug-resistant staphylococcus aureus, is realized.

The present application relates to the application of Staphylococcus aureus toxin protein related gene SA1833 / SA1832 in treating Staphylococcus aureus infection. Specifically, it relates to the application of Staphylococcus aureus toxin protein related gene SA1833 and / or SA1832 as a target in the preparation of a drug for treating drug-resistant Staphylococcus aureus infection, preferably, the drug resistance is preferably methicillin resistance. With SA1833 and / or SA1832 as a target, the clinical treatment of repeated and persistent infection caused by methicillin-resistant Staphylococcus aureus retention has a significant effect. It provides a new target for the development of drugs for treating repeated infection caused by clinical MRSA strains, provides more choices for the treatment of Staphylococcus aureus, and has a wide application prospect.

The invention discloses an antibacterial peptide derived from bullfrog skin and application of the antibacterial peptide. The amino acid sequence of the antibacterial peptide is GSVGPVGPR (as shown in SEQ ID NO: 1), and the molecular weight of the antibacterial peptide is 824.4504 g / mol. The antibacterial peptide disclosed by the invention has an obvious inhibiting effect on staphylococcus aureus and can be used for preparing a medicine for preventing or inhibiting staphylococcus aureus infection. Meanwhile, when the antibacterial peptide and the vitamin A are combined for use, the antibacterial peptide shows a remarkable synergistic bactericidal effect on staphylococcus aureus, and when the antibacterial peptide and the vitamin A are combined for use, the use concentration of a single component can be remarkably reduced, the antibacterial efficiency is improved, and the problem of bacterial drug resistance is solved; the compound can be used for preparing antibacterial drugs, skin external preparations, medical dressings, feed additives and food preservatives.

The application provides a recombinant chicken antibacterial peptide against drug-resistant Staphylococcus aureus and belongs to the field of veterinary technology. The recombinant chicken antibacterial peptide is expressed by genetically engineering recombinant Escherichia coli. Three active regions of natural chicken antibacterial peptides are fused, and two disulfide bonds are introduced to stabilize the structure of the recombinant chicken antibacterial peptide and enhance the affinity of the recombinant chicken antibacterial peptide to the outer membrane protein of Staphylococcus aureus. The minimum inhibitory concentration of the recombinant chicken antibacterial peptide to drug-resistant Staphylococcus aureus is significantly lower than that of the three natural chicken antibacterial peptides, and the minimum inhibitory concentration of 8 μg / mL can completely inhibit the formation of a biological membrane of a drug-resistant Staphylococcus aureus USA300 strain. The recombinant chicken antibacterial peptide has good antibacterial effect on different drug-resistant Staphylococcus aureus isolated from a chicken farm, and can effectively solve the problem of drug-resistant Staphylococcus aureus infection in the chicken farm.

This invention relates to the fields of biomedicine and immunology, and particularly to the preparation and application of an anti-Staphylococcal enterotoxin B antibody. The antibody provided by this invention has a SEB-A8 heavy chain variable region containing CDR sequences as shown in SEQ ID NO:1-3, and a light chain variable region containing CDR sequences as shown in SEQ ID NO:9-11. It has significant application value in the treatment, prevention, and diagnosis of Staphylococcus aureus infections. Experimental data show that this antibody can effectively neutralize the superantigen activity of SEB, significantly improve the survival rate of MRSA-infected mice, and exhibit a dose-dependent protective effect. It can be used as a "non-antibiotic" treatment strategy for the treatment of methicillin-resistant Staphylococcus aureus infections, which is of great significance in controlling the development of bacterial resistance and provides a new research direction for clinical anti-infective therapy.

The application discloses application of total flavones of radix scutellariae combined with tetracycline antibiotics in preparation of products against staphylococcus aureus, and belongs to the technical field of medicines. The application provides an antibacterial composition containing total flavones of radix scutellariae and tetracycline antibiotics, aiming at the problems of high drug resistance rate and great toxic side effects of tetracycline antibiotics in the treatment of staphylococcus aureus and methicillin-resistant staphylococcus aureus infection. The total flavones of radix scutellariae contain more than 89% of flavones, and contain various active ingredients such as baicalin and baicalein. The tetracycline antibiotics are selected from doxycycline or minocycline. In vitro experiments prove that the combination of the two has a significant synergistic antibacterial effect on staphylococcus aureus and drug-resistant staphylococcus aureus, and the dosage of doxycycline or minocycline can be reduced by 75%, thereby effectively reducing the toxic side effects.

The invention relates to the technical field of biology, and particularly discloses a phage-sourced staphylococcus aureus antibacterial peptidase lysolytic protein mutant with high thermal stability as well as a preparation method and application of the phage-sourced staphylococcus aureus antibacterial peptidase lysolytic protein mutant. According to the mutant, stability design is carried out on wild type staphylococcus aureus antibacterial peptidase lysostaphin (APL) through a PROSS online prediction tool, nine mutation schemes (design 1-design 9) are obtained, the thermal stability of the mutant APL (design 9) is remarkably improved, the optimal temperature is increased to 55 DEG C, 70 DEG C and 80 DEG C, and the half-life period reaches 57 + / -4 min and 21 + / -1 min respectively and is 1.4 times and 2.1 times of the half-life period of the wild type. The preparation method comprises the steps of gene synthesis, vector construction, recombinant expression and purification. The mutant can be used for preventing and treating staphylococcus aureus infection, veterinary antibiotic substitutes, food preservatives and compound disinfectants, is suitable for a high-temperature processing environment, and has industrialization advantages.

The invention belongs to the technical field of bioengineering, and provides a staphylococcus aureus bacteriophage and application thereof. The staphylococcus aureus bacteriophage provided by the invention is XHX-SA-1P, is preserved in the China Center for Type Culture Collection, has the preservation number of CCTCC NO: M2025494, and is classified and named as the staphylococcus aureus bacteriophage, the bacteriophage is obtained by separating and purifying an infected sample, the lysis spectrum is wide, the lysis efficiency is high, and the staphylococcus aureus bacteriophage has good environmental stability and multiplication capacity; the bacteriophage can be used for preparing an oral preparation, a freeze-drying preparation or a microcapsule preparation, can also be used as an active ingredient of a feed additive, and is used for preventing or treating diseases related to staphylococcus aureus infection of poultry and improving the biosafety level and the prevention and control effect in the breeding process.

The invention discloses an application of a compound 3546847 in preparation of anti-staphylococcus aureus hemolysin medicines, and belongs to the field of microbial infectious diseases and medicines. The invention finds that the compound 3546847 can neutralize the toxicity of staphylococcus aureus hemolysin, and has a protective effect on MRSA staphylococcus aureus USA300 infected mice. The compound 3546847 can be applied to preparation of anti-staphylococcus aureus hemolysin medicines and medicines for preventing or treating staphylococcus aureus infection. The new medicinal value of the compound 3546847 is found, and a new medicine for preventing and treating staphylococcus aureus infection is provided; the compound 3546847 can neutralize the main virulence factor of staphylococcus aureus, namely hemolysin, so as to relieve inflammatory injury.

This disclosure provides a method reducing the number of Staphylococcus aureus bacterial cells in a subject and a method of treating or preventing diseases or disorders caused by S. aureus. This disclosure also provides a method of diagnosis or prognosis of a disease or disorder caused by S. aureus.

The invention provides an anti-staphylococcus aureus specific antibody as well as a nucleic acid coding sequence and application thereof. The anti-staphylococcus aureus specific antibody provided by the invention achieves the effects of treating staphylococcus aureus infection and enhancing immune cells against staphylococcus aureus through a plurality of efficacy experiments.

The application relates to the technical field of biotechnology, and particularly discloses a bacteriophage-derived lysostaphin mutant with high thermal stability and an application and a preparation method thereof. The mutant is obtained by using a PROSS online prediction tool to design the stability of wild-type antimicrobial peptidase lysostaphin (APL), and nine mutation schemes (design 1-design 9) are obtained. The thermal stability of the mutant APL (design 9) is significantly improved, the optimum temperature is increased to 55 DEG C, and the half-life at 70 DEG C and 80 DEG C is 57+ / -4 min and 21+ / -1 min, respectively, which is 1.4 times and 2.1 times that of the wild type. The preparation method comprises gene synthesis, vector construction, recombinant expression and purification. The mutant can be used for the prevention and treatment of staphylococcus aureus infection, veterinary antibiotic substitutes, food preservatives and compound disinfectants, and is suitable for high-temperature processing environment and has industrialization advantages.

This invention discloses a fully human monoclonal antibody Hm0699 against Staphylococcus aureus α-hemolysin and its applications. The antibody comprises a heavy chain and a light chain. The amino acid sequences of the variable regions CDR1, CDR2, and CDR3 of the heavy chain are shown in SEQ ID NO. 5, SEQ ID NO. 6, and SEQ ID NO. 7; the amino acid sequences of the variable regions CDR1, CDR2, and CDR3 of the light chain are shown in SEQ ID NO. 8, SEQ ID NO. 9, and SEQ ID NO. 10. This antibody can specifically bind to Staphylococcus aureus α-hemolysin and can be used for the treatment, prevention, or diagnosis of Staphylococcus aureus infections. It represents an important direction in the research field of "non-antibiotic" treatment of methicillin-resistant Staphylococcus aureus infections and control of drug resistance development.